RDIF, Alium, R-Pharm to invest in production of COVID-19 vaccines
MOSCOW, Jun 5 (PRIME) -- The Russian Direct Investment Fund (RDIF), multi-industry holding Sistema and their pharmaceutical company Alium, as well as R-Pharm will invest in production of two coronavirus vaccines jointly with the Gamaleya Research Center for Epidemiology and Microbiology of the Healthcare Ministry, RDIF CEO Kirill Dmitriev told President Vladimir Putin on Friday.
“We announce for the first time today that together with our portfolio company Alium, Sistema holding and R-Pharm, we will invest in production of two vaccines together with the Gamaleya Institute. We believe that this vaccine shows good results. After it is provided for Russia, it can be one of the world leaders in terms of vaccines,” Dmitriev said.
He also said that the RDIF has created a joint venture with National Immunobiological Company, or Nacimbio, of state-run corporation Rostec to produce drugs against coronavirus based on blood plasma.
“We also created a joint venture with Nacimbio of Rostec to produce (a drug based on) antibodies to the virus based on blood plasma,” Dmitriev said.
He also said that the Avifavir pharmaceutical product against the coronavirus will be free of charge in Russia within the framework of the compulsory health insurance.
“Clinical trials allow us to consider this drug one of the most promising in the world. It will be delivered to clinics in Russia already on June 11, and will be provided free of charge for Russians under the compulsory medical insurance program,” he said.
The RDIF has sold over 10 million coronavirus tests abroad, Dmitriev also said.
“After we met the needs of Russia, we have already sold more than 10 million tests to other countries, and these countries buy these tests because they know that these are one of the best tests,” he said.